This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The Food and Drug Administration prohibited marketing of one long-acting sulfonamide mixture and ordered stiff warning requirements for other preparations.Madricidin, made by Hoffmann-La Roche, Inc., was ordered withdrawn on grounds there is lack of substantial evidence it is effective in treating the common cold. FDA Commissioner James Goddard, MD, also said it can produce dangerous and sometimes fatal side effects known as the Stevens-Johnson syndrome.Other long-acting sulfa products (sulfadimethoxine and sulfamethoxypyridazine) made by Hoffmann-La Roche, Parke Davis & Co., and Lederle laboratories, and used to combat bacterial infections, must carry the label statement that since short-acting sulfa products are effective "for the same conditions their use should be ruled out before the long-acting sulfonamides are employed."According to the FDA, the long-acting drugs have been associated with 81 cases of Stevens-Johnson syndrome in the United States.Products affected are Madribon tablets, Madribon Chewing tablets and Madribon
WASHINGTON NEWS. JAMA. 1966;195(13):21-23. doi:10.1001/jama.1966.03100130011003